Search results for "language"

showing 10 items of 16993 documents

Understanding illnesses through a film festival: an observational study

2019

Abstract Audio-visual materials play a fundamental role in the context of education, care and clinical treatment, as they seem to have a high impact on public awareness. This study aims to describe what messages are perceived by the society at an International Festival of Short Films and Art on Diseases that may help to understand difficult topics, such as illness, dying and suffering. Through an observational, descriptive, cross-sectional study, using full participant observation and an open, self-administered questionnaire, 32 short films were analysed during a healthcare art festival. Categories were developed using inductive content analysis. The message perceived by the participants, a…

0301 basic medicinePositive educationmedia_common.quotation_subjectContext (language use)ObservationParticipant observationArticleEducation03 medical and health sciences0302 clinical medicineSociologyHealth carePublic awarenessMeaning of lifeIllnessmedia_commonMedical educationMultidisciplinarybusiness.industryHealthcareAudio-visual030104 developmental biologyContent analysisHealthcare IllnessSocial dialogueObservational studybusinessPsychology030217 neurology & neurosurgery
researchProduct

7q31.32 partial duplication: First report of a child with dysmorphism, autistic spectrum disorder, moderate intellectual disability and, epilepsy. Li…

2019

Abstract Introduction Duplication of long arm of chromosome 7(q) is uncommon. It may occur as “pure”, isolated anomaly or in association with other mutations involving the same or other chromosomes. “Pure” chromosome 7q duplication has recently been classified by segment involved: the interstitial, proximal, or distal segment of the arm. Attempts to correlate genotype with phenotype in each group has yielded questionable results even though intellective disability and minor dysmorphic features of variable types are typically seen. Material and Methods In a young boy showing minor facial dysmorphism, language delay, autistic spectrum disorder, epileptic seizures, behavioral disturbances and …

0301 basic medicineProbandPediatricsmedicine.medical_specialtyAutism Spectrum DisorderLanguage delayDevelopmental DisabilitiesIrritabilityChromosomes03 medical and health sciencesEpilepsy0302 clinical medicineIntellectual DisabilityGene duplicationIntellectual disabilityHumansMedicineGenetic Association StudiesChromosome 7 (human)Epilepsybusiness.industrymedicine.disease7q31.32 duplicationDysmorphism030104 developmental biologyAutistic spectrum disorderNeurologyAutism spectrum disorderPair 7Neurology (clinical)medicine.symptombusinessChromosomes Human Pair 7030217 neurology & neurosurgeryHumanEpilepsy Research
researchProduct

Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease.

2017

// Antonino Tuttolomondo 1 , Irene Simonetta 1 , Giovanni Duro 2 , Rosaria Pecoraro 1 , Salvatore Miceli 1 , Paolo Colomba 2 , Carmela Zizzo 2 , Antonia Nucera 3, 4 , Mario Daidone 1 , Tiziana Di Chiara 1 , Rosario Scaglione 1 , Vittoriano Della Corte 1 , Francesca Corpora 1 , Danai Vogiatzis 1 and Antonio Pinto 1 1 U.O.C di Medicina Interna con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), University of Palermo, Palermo, Italy 2 CNR-IBIM: Institute of Biomedicine and Molecular Immunology “A. Monroy” Palermo, Palermo, Italy 3 Stroke Unit, Neurology, Saint Andrea Hospital, La Spezia, Italy 4 Department of Clinical Neurological Sciences, Western Univer…

0301 basic medicineProbandmedicine.medical_specialtyPediatricsNeurologyfamilySettore MED/09 - Medicina InternaDiseaseGene mutationAnderson-Fabry disease (AFD)Pathogenesis03 medical and health sciences0302 clinical medicineAnderson-Fabry disease (AFD); family; variabilitymedicineGeneticsbusiness.industryvariabilityOrgan dysfunctionmedicine.diseaseFabry diseaselanguage.human_language030104 developmental biologyOncologylanguagemedicine.symptombusinessSicilian030217 neurology & neurosurgeryResearch Paper
researchProduct

Narrowing the Genetic Causes of Language Dysfunction in the 1q21.1 Microduplication Syndrome

2018

The chromosome 1q21.1 duplication syndrome (OMIM# 612475) is characterized by head anomalies, mild facial dysmorphisms, and cognitive problems, including autistic features, mental retardation, developmental delay, and learning disabilities. Speech and language development are sometimes impaired, but no detailed characterization of language problems in this condition has been provided to date. We report in detail on the cognitive and language phenotype of a child who presents with a duplication in 1q21.1 (arr[hg19] 1q21.1q21.2(145,764,455-147,824,207) × 3), and who exhibits cognitive delay and behavioral disturbances. Language is significantly perturbed, being the expressive domain the most …

0301 basic medicineProbandmedicine.medical_specialtycognitive delayAudiologychromosome 1q21.1 duplication syndrome03 medical and health sciences0302 clinical medicineMotor speechmedicinebusiness.industrylanguage deficitslcsh:RJ1-570DyslexiaCDH1LROBO1lcsh:PediatricsCognitionFOXP2Pragmaticsmedicine.diseaseComprehensionLanguage development030104 developmental biologyPediatrics Perinatology and Child Healthspeech problemsbusiness030217 neurology & neurosurgery
researchProduct

Permeating disciplines: Overcoming barriers between molecular simulations and classical structure-function approaches in biological ion transport

2017

Ion translocation across biological barriers is a fundamental requirement for life. In many cases, controlling this process-for example with neuroactive drugs-demands an understanding of rapid and reversible structural changes in membrane-embedded proteins, including ion channels and transporters. Classical approaches to electrophysiology and structural biology have provided valuable insights into several such proteins over macroscopic, often discontinuous scales of space and time. Integrating these observations into meaningful mechanistic models now relies increasingly on computational methods, particularly molecular dynamics simulations, while surfacing important challenges in data manage…

0301 basic medicineProtein ConformationComputer sciencemedia_common.quotation_subjectData managementBiophysicsContext (language use)Molecular Dynamics SimulationBiochemistryIon ChannelsArticleStructure-Activity Relationship03 medical and health sciencesAnimalsHumansFunction (engineering)Biological sciencesClassical structureIon transportermedia_commonIon Transportbusiness.industryMembrane Transport ProteinsCell BiologyData science030104 developmental biologyStructural biologybusinessIon Channel GatingProtein BindingBiochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

Biomarkers in Anderson–Fabry Disease

2020

Fabry disease is a rare lysosomal storage disorder caused by a deficiency of α-galactosidase A, resulting in multisystemic involvement. Lyso-Gb3 (globotriaosylsphingosine), the deacylated form of Gb3, is currently measured in plasma as a biomarker of classic Fabry disease. Intensive research of biomarkers has been conducted over the years, in order to detect novel markers that may potentially be used in clinical practice as a screening tool, in the context of the diagnostic process and as an indicator of response to treatment. An interesting field of application of such biomarkers is the management of female heterozygotes who present difficulty in predictable clinical progression. This revi…

0301 basic medicineProteomeContext (language use)ReviewDisease030204 cardiovascular system & hematologylyso-Gb3BioinformaticsCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansPhysical and Theoretical Chemistryfabrylcsh:QH301-705.5Molecular BiologySpectroscopybusiness.industryMolecular pathologyOrganic ChemistryClinical coursebiomarkersBiomarkerGeneral Medicinemedicine.diseaseResponse to treatmentFabry diseaseComputer Science ApplicationsMicroRNAsAnderson-Fabry Disease030104 developmental biologylcsh:Biology (General)lcsh:QD1-999MetabolomeFabry DiseaseBiomarker (medicine)businessInternational Journal of Molecular Sciences
researchProduct

Extracellular vesicles in food: Experimental evidence of their secretion in grape fruits

2017

In the last decade, the number of studies related with extracellular vesicles (EVs) has dramatically grown since their role as key part of intercellular communication has been confirmed. EVs, as transporter of distinct bioactive molecules, can take part in different physiological mechanisms and have been gaining attention as potential tools with a wide range of therapeutic effects. Whereas a high number of studies have been published related to mammalian derived EVs, including products as food source, the existence of EVs in plants still is controversial. Recent descriptions of vesicles derived from edible plants show that they might contain pharmacological active molecules. In this context…

0301 basic medicineProteomicsSecretion Grape berryBioactive moleculesPharmaceutical ScienceContext (language use)BiologyExtracellular vesicles03 medical and health sciencesExtracellular VesiclesAnimalsHumansSecretionGrape berryVitisVitis viniferaPlant Proteinsfood and beveragesFood exosomesExtracellular vesiclesMicrovesiclesFruit and Vegetable Juices030104 developmental biologyMilkBiochemistryFruitVitis viniferaEdible plants
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.

2019

Approximately one third of patients with non-small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based c…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyDurvalumabLung Neoplasmsmedicine.medical_treatmentContext (language use)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansLung cancerSurvival rateImmune Checkpoint InhibitorsPneumonitisbusiness.industryChemoradiotherapyPneumoniamedicine.diseasePrognosisImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessChemoradiotherapyClinical lung cancer
researchProduct

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung can…

2020

The introduction of licensed front-line immunotherapies has heralded a new era for the treatment of non-oncogene-addicted, advanced non-small cell lung cancer (NSCLC). Yet as with all evolutions in clinical management, changes in practice can outpace the availability of the clinical evidence needed to inform subsequent therapeutic decision making. At the time of writing, there is limited available evidence on the optimum therapeutic options after progression on immunotherapy. Further research is needed to define mechanisms of immunotherapy resistance in patients with advanced NSCLC, and to understand the implications for subsequent treatment response. Pending the availability of robust clin…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentNintedanibContext (language use)Angiogenesis InhibitorsAnti-angiogenic drugNon-oncogene-addicted non-small cell lung cancer (NSCLC)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineTumor MicroenvironmentHumansTumor microenvironment (TME)Lung cancerImmune Checkpoint InhibitorsTumor microenvironmentAnti-angiogenic drug; Immunotherapy resistance; Nintedanib; Non-oncogene-addicted non-small cell lung cancer (NSCLC); Tumor microenvironment (TME); Vascular endothelial growth factor (VEGF)Oncogenebusiness.industryVascular endothelial growth factor (VEGF)ImmunosuppressionImmunotherapymedicine.diseaseImmunotherapy resistance030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisNintedanibNon small cellImmunotherapybusiness
researchProduct